Join Jack McDonnell, MD, a pediatric immunologist and assistant professor at Cleveland Clinic Lerner College of Medicine, and Elie Haddad, MD, PhD, a clinician-researcher in pediatric immunology, full professor at the University of Montreal, and head of the Immunology and Rheumatology department at CHU Sainte-Justine, as they explore the evolving world of immune deficiency and dysregulation.
Presented by the Primary Immune Deficiency Treatment Consortium (PIDTC), this podcast features conversations with leading experts, pioneering researchers, patients, and advocacy groups. Each episode uncovers cutting-edge research, clinical challenges, and personal stories—ensuring that the patient voice remains at the center of the discussion.
Whether you're a clinician, researcher, patient, or advocate, Immune Matters brings you the latest insights in diagnosis, treatment, and innovation in primary immune disorders.
Tune in to explore the science, the stories, and the future of immune health.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
All content for Immune Matters: a PIDTC Podcast is the property of Jack McDonnell and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Jack McDonnell, MD, a pediatric immunologist and assistant professor at Cleveland Clinic Lerner College of Medicine, and Elie Haddad, MD, PhD, a clinician-researcher in pediatric immunology, full professor at the University of Montreal, and head of the Immunology and Rheumatology department at CHU Sainte-Justine, as they explore the evolving world of immune deficiency and dysregulation.
Presented by the Primary Immune Deficiency Treatment Consortium (PIDTC), this podcast features conversations with leading experts, pioneering researchers, patients, and advocacy groups. Each episode uncovers cutting-edge research, clinical challenges, and personal stories—ensuring that the patient voice remains at the center of the discussion.
Whether you're a clinician, researcher, patient, or advocate, Immune Matters brings you the latest insights in diagnosis, treatment, and innovation in primary immune disorders.
Tune in to explore the science, the stories, and the future of immune health.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
Immune Matters Episode 4, Rebecca and Dani, Chiron
Immune Matters: a PIDTC Podcast
30 minutes
1 month ago
Immune Matters Episode 4, Rebecca and Dani, Chiron
In this episode of Immune Matters, hosts Jack and Elie discuss the Chiron platform with guests Dr. Rebecca Marsh and Dr. Dani Arnold. Chiron is a data interaction tool designed by the PIDTC for researchers in the field of immune deficiency. Dr. Marsh and Dr. Arnold explore Chiron's features and clinical applications, emphasizing its potential to enhance patient care and research outcomes. The conversation also touches on future developments and access to the platform for investigators.
Keywords: immune deficiency, immune dysregulation, Chiron platform, PIDTC, patient experience, data interaction, clinical research, transplant outcomes, immune disorders, healthcare technology
Immune Matters: a PIDTC Podcast
Join Jack McDonnell, MD, a pediatric immunologist and assistant professor at Cleveland Clinic Lerner College of Medicine, and Elie Haddad, MD, PhD, a clinician-researcher in pediatric immunology, full professor at the University of Montreal, and head of the Immunology and Rheumatology department at CHU Sainte-Justine, as they explore the evolving world of immune deficiency and dysregulation.
Presented by the Primary Immune Deficiency Treatment Consortium (PIDTC), this podcast features conversations with leading experts, pioneering researchers, patients, and advocacy groups. Each episode uncovers cutting-edge research, clinical challenges, and personal stories—ensuring that the patient voice remains at the center of the discussion.
Whether you're a clinician, researcher, patient, or advocate, Immune Matters brings you the latest insights in diagnosis, treatment, and innovation in primary immune disorders.
Tune in to explore the science, the stories, and the future of immune health.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
